arrow_back Trending Legislation
Share share

Increased funding for research and treatment of blood disorders, including sickle cell disease.

This act increases funding for research, surveillance, prevention, and treatment programs for sickle cell disease and other inherited blood disorders. This means more money will be allocated to combat these conditions, potentially improving access to care and innovative therapies for affected individuals.
Key points
Annual funding for blood disorder programs increased from $4.455 million to $8.205 million for fiscal years 2024-2028.
Expanded funding options to include grants and cooperative agreements, in addition to existing contracts, for research and treatment.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Print number: HR 3884
Sponsor: Rep. Burgess, Michael C. [R-TX-26]
Process start date: 2023-06-07
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased funding for research and treatment of blood disorders, including sickle cell disease.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3884.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-07.

What are the main provisions?

Key points include:

  • Annual funding for blood disorder programs increased from $4.455 million to $8.205 million for fiscal years 2024-2028.
  • Expanded funding options to include grants and cooperative agreements, in addition to existing contracts, for research and treatment.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Burgess, Michael C. [R-TX-26].

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 3884

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health